eif gathering momentum, page-3

Thanks for your views, asdfgf. I agree that it pays to be circumspect with companies that are yet to get many runs on the board. Nevertheless, even a few crumbs from the big boys' table would be sufficient to make the company's operations very profitable indeed.

On the company's website, attention is drawn to EIF's competitive advantage in having 'capability in all four SCF technologies' whereas other major competitors have capability in only one or two. Presumably this broadens the range of drugs the company is able to re-engineer and hence its attractiveness to potential customers - "the one-stop shop" idea.

I realize it is a big leap from 'having potential' to 'confirmed deal' stage but the CEO stated recently (in May, I think) that 'Eiffel expects to announce major collaborations within the coming months.' The completion of a research facility capable of conducting clinical trials in 1st quarter 2004 should also enhance the company's appeal to pharmaceutical companies looking to extend the patent life of their drugs.

Altogether, I think the company has an interesting future if cash burn does not exceed revenue stream (the recent successful share placement seems to have boosted the coffers significantly), despite the inherent risks you rightly allude to.

Any chartists have a view?

Regards, Gupper